FeesSafety
Pluang+

Celldex Therapeutics upgraded to Buy after positive Phase 3 trial results for skin drug barzolvolimab.

Analyst Insights
23 Sep 2026, 00:00 WIB
Stuart Mooney
View Source
Bullish
Celldex Therapeutics upgraded to Buy after positive Phase 3 trial results for skin drug barzolvolimab.

Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chronic skin condition not well-controlled by antihistamines. Nearly 2,000 patients across 43 countries participated in the trials, which met all primary goals. Celldex plans to submit for FDA approval in 2027, signaling significant progress in its drug development pipeline.

Celldex Therapeutics and its recent analyst upgrade provide context for health-sector activity on Pluang. For readers following health stocks, 78 of 101 priced US health-sector stocks rose today. Notable movers include Aurora Cannabis Inc (ACB) at USD 4.22 with a 4.84% increase, Amgen, Inc. (AMGN) at USD 410.00 with a 4.28% increase, and Recursion Pharmaceuticals Inc (RXRX) at USD 4.13 with a 4.16% increase. These figures are as of Sep 23, 2026 02:01 WIB.

More News

NSCLC market set to double by 2036 as biomarker-driven treatments advance at ESMO 2026.

NSCLC market set to double by 2036 as biomarker-driven treatments advance at ESMO 2026.

The non-small cell lung cancer (NSCLC) market across seven major countries is projected to grow from USD 33 billion in 2025 to about USD 67 billion by 2036, driven by advances in biomarker-guided therapies highlighted at the ESMO 2026 Congress. Key P...

Market News
Bullish
1 hour ago
Investing in the S&P 500 since 2000 grew $1,000 to $8,050 despite a 13-year flat period.

Investing in the S&P 500 since 2000 grew $1,000 to $8,050 despite a 13-year flat period.

Investing in the S&P 500 at the tech bubble peak in 2000 led to over a decade of flat returns, but staying invested paid off. Since March 24, 2000, the S&P 500 has returned 705% with dividends reinvested, turning $1,000 into $8,050, averaging just ov...

Market News
Bullish
1 hour ago
GTA VI breaks records with $1.65B sales and near-perfect reviews at launch.

GTA VI breaks records with $1.65B sales and near-perfect reviews at launch.

Grand Theft Auto VI has launched with a record-breaking start, selling 17.07 million units worth $1.65 billion in its first 24 hours, more than doubling the debut sales of GTA V. The game has received overwhelmingly positive reviews, including a near...

Market News
Bullish
1 hour ago
Amazon forecasts Q4 operating income up 14-34%, driven by strong ad growth and sales efficiency.

Amazon forecasts Q4 operating income up 14-34%, driven by strong ad growth and sales efficiency.

Amazon expects its Q4 operating income to rise to $28.5-$33.5 billion, a 14-34% increase from last year, on sales growth of 12-16%. This profit growth outpaces sales growth, signaling improved efficiency. Advertising revenue, the most profitable part...

Company Fundamentals
Bullish
1 hour ago
Cerebras and IonQ race in AI and quantum computing with strong growth but high risks for 2027.

Cerebras and IonQ race in AI and quantum computing with strong growth but high risks for 2027.

Cerebras Systems and IonQ represent two cutting-edge tech fields: AI hardware and quantum computing. Cerebras focuses on large wafer-scale processors for AI workloads, showing strong revenue growth and a solid cash reserve but faces manufacturing and...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App